CYP2D6 genotype and tamoxifen response

被引:0
作者
James M Rae
Matthew P Goetz
Daniel F Hayes
James N Ingle
Lang Li
Anna Maria Storniolo
Vered Stearns
David A Flockhart
机构
[1] University of Michigan Medical Center,Department of Internal Medicine
来源
Breast Cancer Research | / 7卷
关键词
Tamoxifen; Postmenopausal Breast Cancer; Adjuvant Tamoxifen; CYP2D6 Genotype; Postmenopausal Breast Cancer Patient;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
相关论文
共 36 条
[1]  
Wegman P(2005)Genotype of metabolic enzymes and the benefit of tamoxifen in postmenopausal breast cancer patients Breast Cancer Res 7 R284-R290
[2]  
Vainikka L(2004)Pharmacogenomic determinants of outcome with tamoxifen therapy: findings from the randomized North Central Cancer Treatment Group adjuvant breast cancer trial 89-30-52 Breast Cancer Res Treat 88 S35-1764
[3]  
Stal O(2003)Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine J Natl Cancer Inst 95 1758-39
[4]  
Nordenskjold B(2005)CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment J Natl Cancer Inst 97 30-undefined
[5]  
Skoog L(undefined)undefined undefined undefined undefined-undefined
[6]  
Rutqvist LE(undefined)undefined undefined undefined undefined-undefined
[7]  
Wingreb S(undefined)undefined undefined undefined undefined-undefined
[8]  
Goetz MP(undefined)undefined undefined undefined undefined-undefined
[9]  
Rae JM(undefined)undefined undefined undefined undefined-undefined
[10]  
Suman VJ(undefined)undefined undefined undefined undefined-undefined